Gemmer Asset Management LLC raised its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 5.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 686 shares of the life sciences company’s stock after buying an additional 37 shares during the period. Gemmer Asset Management LLC’s holdings in Illumina were worth $117,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Acadian Asset Management LLC raised its position in Illumina by 247.8% in the third quarter. Acadian Asset Management LLC now owns 13,692 shares of the life sciences company’s stock valued at $2,487,000 after buying an additional 9,755 shares during the last quarter. California Public Employees Retirement System raised its stake in Illumina by 0.5% in the third quarter. California Public Employees Retirement System now owns 322,600 shares of the life sciences company’s stock worth $58,604,000 after buying an additional 1,600 shares in the last quarter. Cypress Asset Management Inc. TX raised its stake in Illumina by 17.9% in the third quarter. Cypress Asset Management Inc. TX now owns 2,310 shares of the life sciences company’s stock worth $420,000 after buying an additional 350 shares in the last quarter. Henderson Group PLC raised its stake in Illumina by 2.5% in the third quarter. Henderson Group PLC now owns 19,235 shares of the life sciences company’s stock worth $3,494,000 after buying an additional 461 shares in the last quarter. Finally, Boston Advisors LLC purchased a new stake in Illumina during the third quarter worth about $1,717,000. Hedge funds and other institutional investors own 92.79% of the company’s stock.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded down 0.44% during midday trading on Thursday, hitting $177.24. 894,487 shares of the company were exchanged. The company’s 50 day moving average price is $169.01 and its 200 day moving average price is $152.14. The firm has a market cap of $25.93 billion, a P/E ratio of 57.73 and a beta of 0.79. Illumina, Inc. has a one year low of $119.37 and a one year high of $186.88.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, January 31st. The life sciences company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.03. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The business had revenue of $619 million for the quarter, compared to the consensus estimate of $612.50 million. During the same period in the prior year, the business earned $0.81 EPS. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. Equities analysts expect that Illumina, Inc. will post $3.64 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at http://www.wkrb13.com/markets/2065224/illumina-inc-ilmn-shares-bought-by-gemmer-asset-management-llc.html.
ILMN has been the topic of a number of analyst reports. BTIG Research reiterated a “hold” rating on shares of Illumina in a research note on Sunday, March 19th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $191.00 price target for the company in a research report on Tuesday, April 4th. Vetr downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $193.40 price target for the company. in a research report on Tuesday, April 11th. Janney Montgomery Scott reissued a “sell” rating and set a $125.00 price target on shares of Illumina in a research report on Friday, January 6th. Finally, Bank of America Corp raised their price target on shares of Illumina from $175.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, April 11th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $161.22.
In related news, SVP Charles Dadswell sold 572 shares of the company’s stock in a transaction that occurred on Monday, February 6th. The stock was sold at an average price of $161.26, for a total transaction of $92,240.72. Following the transaction, the senior vice president now directly owns 7,592 shares of the company’s stock, valued at approximately $1,224,285.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director A Blaine Bowman sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 12th. The stock was sold at an average price of $172.72, for a total value of $518,160.00. Following the transaction, the director now directly owns 18,704 shares in the company, valued at $3,230,554.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,476 shares of company stock worth $2,078,440. 1.60% of the stock is owned by company insiders.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2065224/illumina-inc-ilmn-shares-bought-by-gemmer-asset-management-llc.html
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.